Reurink Gustaaf, Goudswaard Gert Jan, Moen Maarten H, Weir Adam, Verhaar Jan A N, Tol Johannes L
Room Hs-104, Department of Orthopedics, Erasmus Medical Centre, PO Box 2040, 3000 CA, Rotterdam, The Netherlands,
Sports Med. 2014 Jul;44(7):943-56. doi: 10.1007/s40279-014-0186-6.
Injection therapies are widely used for muscle injuries. As there is only limited evidence of their efficacy, physicians should be aware of the potential harmful effects of these injected preparations.
The purpose of this review was to systematically review the literature on the myotoxic effects of intramuscular injection preparations commonly used for acute muscle injuries.
The databases of PubMed, Embase, Web of Science, Cochrane Library, CINAHL and SportDiscus were searched in March 2013.
Studies reporting histological evaluation or creatine kinase activity after intramuscular injection with local anaesthetics, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), platelet-rich plasma (PRP), Traumeel(®) and Actovegin(®), or combination preparations were eligible for inclusion.
Two authors independently screened the search results and assessed the risk of bias. A best-evidence synthesis was used to identify the level of evidence.
Forty-nine studies were included in this systematic review. There is strong to moderate evidence that intramuscularly injected local anaesthetics and NSAIDs are myotoxic, and there is conflicting evidence of the myotoxicity of PRP. There is limited evidence that single corticosteroid injections are not myotoxic but have a synergistic myotoxic effect when used together with local anaesthetics. There is no information to assess whether Actovegin(®) and Traumeel(®) are myotoxic.
Local anaesthetics and NSAID injections are not recommended for the treatment of muscle injuries in athletes, as they are myotoxic. The possible myotoxic effects of corticosteroids, PRP, Traumeel(®) and Actovegin(®) should be assessed in future research.
注射疗法广泛用于肌肉损伤。由于其疗效证据有限,医生应意识到这些注射制剂的潜在有害影响。
本综述旨在系统回顾常用于急性肌肉损伤的肌肉注射制剂的肌毒性作用的文献。
2013年3月检索了PubMed、Embase、Web of Science、Cochrane图书馆、CINAHL和SportDiscus数据库。
报告局部麻醉剂、皮质类固醇、非甾体抗炎药(NSAIDs)、富血小板血浆(PRP)、伤痛膏(Traumeel®)和爱维治(Actovegin®)或联合制剂肌肉注射后的组织学评估或肌酸激酶活性的研究符合纳入标准。
两位作者独立筛选检索结果并评估偏倚风险。采用最佳证据综合法确定证据水平。
本系统综述纳入了49项研究。有强到中等强度的证据表明肌肉注射局部麻醉剂和NSAIDs具有肌毒性,关于PRP的肌毒性存在相互矛盾的证据。有限的证据表明单次注射皮质类固醇无肌毒性,但与局部麻醉剂联合使用时具有协同肌毒性作用。没有信息可评估爱维治(Actovegin®)和伤痛膏(Traumeel®)是否具有肌毒性。
不建议对运动员的肌肉损伤使用局部麻醉剂和NSAIDs注射治疗,因为它们具有肌毒性。皮质类固醇、PRP、伤痛膏(Traumeel®)和爱维治(Actovegin®)可能的肌毒性作用应在未来研究中评估。